Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02868268Active Not Recruiting

Neuroblastoma Precision Trial

Role: collaborator

NCT03107988Phase 1Completed

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

Role: collaborator

NCT02311621Phase 1Active Not Recruiting

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01

Role: collaborator

NCT01822652Phase 1Active Not Recruiting

3rd Generation GD-2 Chimeric Antigen Receptor and ICaspase Suicide Safety Switch, Neuroblastoma, GRAIN

Role: collaborator

NCT02163356Phase 1Terminated

Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma

Role: collaborator

All 5 trials loaded